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Abstract

Rony, R M Imtiaz Karim. M.S. Department of Biological Sciences, Wright State
University, 2018. Transcriptional characterization of osteogenic and adipogenic
differentiation of human bone marrow derived mesenchymal stem cells in 2D and 3D
peptide hydrogel culture system.

Mesenchymal stem cells (MSCs) are adult multipotent stem cell that can
differentiate into mesodermal lineages such osteoblast, adipocytes, and chondrocytes, or
can be transdifferentiated into clinically relevant lineages such as cardiac or neural cells
using in vitro reprogramming techniques. In addition to the multilineage differentiation
potential, MSCs from most tissue origins such bone marrow derived mesenchymal stem
cells (BM-MSCs) or adipose derived mesenchymal stem cells (AD-MSCs) have immune
modulatory functions which indicate their promise in clinical applications for cell-based
therapy, tissue engineering, and regenerative medicine. In recent years, three-dimensional
(3D) cell culture systems, which utilize 3D scaffolds or hydrogels to provide a
physiological 3D microenvironment that mimics the native extracellular matrix, have been
largely embraced to study cellular function and cell fate determination using different cell
types. Although many investigators have shown that stem cell self-renewal/differentiation
is modulated by the 3D scaffold chemistry and/or its surface topology, less attention has
been given to undercover how such 3D scaffold affects chromatin organization and gene
expression of key developmental regulators or lineage specifiers at the transcription and
translation level during the course of stem cell differentiation. In this novel study, we have
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established a Corning® PuraMatrix™ Peptide Hydrogel based 3D culture system for BMMSCs and have analyzed key transcription factors regulating osteogenic (RUNX2, OSX,
TWIST1) and adipogenic (PPARγ, C/EBPα, CHOP10) differentiation of BM-MSCs grown
in a 2D culture and a PuraMatrix™ peptide hydrogel-based 3D culture. BM-MSCs adopt
a completely different morphology and metabolism when encapsulated in PuraMatrix™
peptide hydrogel. Moreover, expression of these key osteogenic (RUNX2, OSX, TWIST1)
and adipogenic (PPARγ, C/EBPα, CHOP10) transcription factors are differentially
expressed between 2D and 3D culture system at different stages of BM-MSCS
differentiation.
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Chapter 1: Introduction.
Stem cells are group of cells that can self-renew and specialize into different cell
types, based on their differentiation potential or potency. In higher animals, embryonic
stem cells (ESCs) from the inner cell mass (ICM) of the blastocyst stage embryo
orchestrate early embryonic development and give rise to all functional cell types and
tissues - a developmental potential known as pluripotency (Thomson et al., 1998; Nichols
and Smith, 2012). During development, ESCs also give rise to certain tissue specific stem
cells known as adult stem cells. Unlike pluripotent ESCs, adult stem cells such as
hematopoietic stem cells (HSCs) or neural stem cells (NSCs) can only differentiate into
certain lineages and have limited self-renewal ability, hence are characterized as
multipotent (Gonzalez and Bernad, 2012). Nevertheless, the prime function of these adult
stem cells is to replenish damage cells/tissues and maintain tissue homeostasis throughout
the lifespan of an organism (Grandel et al., 2006; Wilson et al., 2008; Bonaguidi et al.,
2011)
Mesenchymal stem cells (MSCs) are adult multipotent stem cells that can selfrenew in vitro, and differentiate into mesodermal lineages (Pittenger et al., 1999).
Typically, MSCs are characterized as plastic adherent, spindle shaped stromal cells that
have fibroblast like morphology (Pittenger et al., 1999). Bone marrow has long been
considered as the key source of MSCs; however, multipotent MSCs or MSC-like cells have
also been isolated from different adult tissues such as skeletal muscle, adipose tissue,
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umbilical cord, amniotic fluid, peripheral blood, dental pulp, etc. (da Silva Meirelles et al.,
2006). Typically, MSCs or MSCs like cell populations from adult tissues show
considerable heterogenicity in terms of cell surface markers and gene expression profile
(Panepucci et al., 2004; Kaltz et al., 2010). To minimize complexities associated with
characterizing true multipotent MSCs populations, the International Society for Cellular
Therapy has proposed defined criteria for characterizing multipotent MSCs. These includes
(1) adherence to plastic in standard culture condition, (2) expression of positive (≥95%+)
marker CD105, CD73, CD90 while being negative (≤2%+) for CD45, CD34, CD14 or
CD11b, CD79a or CD19, HLA-DR, and (3) in vitro differentiation into osteoblasts,
adipocytes, chondroblasts (Dominici et al., 2006). In addition to musculoskeletal tissues,
MSCs can differentiate or transdifferentiate into other lineages such as cardiac cells,
neuronal cells, hepatic cells (Figure 1) (Xu et al., 2004; Tao et al., 2005; Chivu et al., 2009).
In general, MSCs residing in the adult tissues or stem cell niches (e.g. HSCs/niches)
maintain tissue homeostasis by two mechanisms. MSCs either undergo differentiation to
generate functional cells for replenishing damaged cells/tissues or MSCs secrete a variety
of cytokines and growth factors termed trophic factors that regulate the growth and
functionality of surrounding cells or stem cell populations (Uccelli et al., 2008). MSCs in
the bone marrow niche support hematopoietic stem cells (HSCs) self-renewal/quiescence
and prevents their differentiation, either through direct physical interaction or by secreting
array of cytokines/chemokines (Oostendorp et al., 2002; Calvi et al., 2003; Mendez-Ferrer
et al., 2010; Omatsu et al., 2010). BM-MSCs also prevent niche HSCs from undergoing
apoptosis and helps maintain a constant physiological reservoir of HSCs (Wilson and
Trumpp, 2006; Wilson et al., 2008).
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Another key feature of MSCs is that they can modulate the host immune system
and avoid immune rejection. Both in vitro and in vivo studies have found that allogenic or
autologous transplantation of MSCs suppress CD4(+) and CD8(+) T cell function and
proliferation (Di Nicola et al., 2002), inhibit dendritic cells maturation and antigen
presentation function (Nauta et al., 2006), and suppress B cell proliferation by arresting
cell cycle (Corcione et al., 2006).
Owing to their multilineage differentiation and immunomodulatory potential,
MSCs have become a very promising resource for regenerative medicine and tissue
engineering. Many preclinical and clinical studies are now underway, exploring therapeutic
potential of MSCs for the treatment of autoimmune or inflammatory diseases such as
Crohn’s disease or Graft-versus-host disease (Le Blanc and Mougiakakos, 2012). MSCs
are also prime candidates for bone disorders, cartilage and intervertebral disc repair, and
hold great promise for treating ischemic cardiac disease, pulmonary fibrosis, and acute
renal failure (Kariminekoo et al., 2016). In addition to direct allogenic transplantation,
MSCs are now being extensively studied for in vitro tissue engineering. Using chemically
defined 3D hydrogels or scaffolds for structural and mechanical support, MSCs can be
expanded for direct differentiation into complex tissue structure such as bone, cartilage, or
skeletal muscle (Zhang et al., 2015; Adamzyk et al., 2016; Witt et al., 2017).
Despite such potential therapeutic/translational advancements in MSCs biology,
the molecular mechanisms underlying MSCs differentiation and lineage specification is
poorly understood. In particular, how MSCs maintain a balance between osteogenesis and
adipogenesis has always been of great interest since any shift in this balance is associated
with aging (Moerman et al., 2004), obesity (Bredella et al., 2011), and diseases such as
3

osteoporosis (Justesen et al., 2001). Although the key transcription factors (TFs) and
signaling pathways regulating osteogenesis and adipogenesis in MSCs have been
characterized (Chen et al., 2016), how these factors are coregulated at each stage of
differentiation, at both transcriptional and translational level, is still being investigated.
Also, there is considerable interest in characterizing MSC differentiation, particularly the
transcriptional and epigenetic changes accompanying differentiation in 3D culture systems
such as hydrogels or scaffolds, since these matrices mimic the in vivo microenvironment.
With these prospects in mind, in this project we aim at profiling the expression of key TFs
regulating osteogenic and adipogenic differentiation of human bone marrow derived
mesenchymal stem cells (BM-MSCs) at transcriptional and translational level, using 2D
(monolayer)

and

self-assembled

peptide

hydrogel-based

3D

culture

system

(PuraMatrix™). Previous studies showed that TFs RUNX2, Osterix (Osx), DLX3, DLX5,
DLX6, MSX2, FOXC2, TWIST, and PPARγ, C/EBPα, C/EBPβ, C/EBPδ, ADD1, KLF5,
TLE3, and CHOP10 are the key regulators and play a critical role at different stages of
osteogenic and adipogenic differentiation of MSCs, respectively (Zhang et al., 2012).
Therefore, we sought to quantify the mRNA and protein levels of these osteogenic and
adipogenic TFs, at different time points during BM-MSCs differentiation in 2D and 3D
culture systems and distinguish how dimensionality modulates their differentiation and
gene expression pattern. Our experiments have uncovered new insights into the dynamics
of transcriptional regulation underlying osteogenesis and adipogenesis of BM-MSCs,
specifically how gene expression pattern of key TFs change during the course of
differentiation, and between 2D and 3D culture systems.
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Figure 1: Multipotency of mesenchymal stem cells (MSCs). MSCs can self-renew to
produce more MSCs or can differentiation into mesodermal lineages such as adipocytes,
osteoblasts, or chondrocytes. MSCs can also transdifferentiate into other lineages within
ectoderm or endoderm.
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Chapter 2: Background
2.1 Bone marrow and adipose derived mesenchymal stem cells:
Bone marrow (BM-MSCs) and adipose derived MSCs (AD-MSCs) are the most
extensively investigated multipotent MSCs owing to their availability and ease of isolation.
Both of these cell types, irrespective of their tissue origin, show fibroblast morphology,
express typical MSCs markers (positive for CD29, CD44, CD105, CD166 while being
negative for CD14, CD45), and can differentiate into osteogenic, adipogenic, and
chondrogenic lineages (Lee et al., 2004; Peng et al., 2008).
However, reports suggest that there are some inherent differences between BMMSCs and AD-MSCs (Zuk et al., 2002; De Ugarte et al., 2003; Lee et al., 2004; Peng et
al., 2008). Morphologically, BM-MSCs colonies have been found to be slightly bigger than
AD-MSCs although AD-MSCs possess higher proliferative ability (Figure.2) (Lee et al.,
2004; Peng et al., 2008). In contrast, AD-MSCs have higher resistance towards serum
deprivation-induced apoptosis (Peng et al., 2008), and higher immunomodulatory potential
than BM-MSCs (Dominici et al., 2006). Only AD-MSCs are positive for CD49d, CD54,
CD34, CD106, and CD49d whereas the expression of CD106 is only detected in BM-MSCs
(Zuk et al., 2002; De Ugarte et al., 2003). Some cytokines are also thought to be
differentially expressed, due to their difference in tissue specificity (Li et al., 2015).
Regardless of these similarities and differences, most of the key transcription factors (e.g.
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RUNX2, PPARγ, etc.) and their regulatory mechanisms underlying MSCs self-renewal and
differentiation are expected to be similar in both cell types.
2.2 Transcriptional Regulations of mesenchymal stem cells osteogenesis and
adipogenesis:
Previous studies have established that differentiation of MSCs is governed by a
transcriptional network comprised of core TFs, cofactors, signaling pathways, and other
regulators such as non-coding RNA (miRNA, lncRNA) and chromatin modifiers that act
in concert to specify osteogenic, adipogenic, or chondrogenic specialization (Guo et al.,
2011; Zhang et al., 2012; Saidi et al., 2017).
For osteogenic differentiation of MSCs, TF Runx2 (Zheng et al., 2004), Osx
(Nakashima et al., 2002), Dlx3 (Hassan et al., 2004), Dlx5 (Ryoo et al., 1997) (Shirakabe
et al., 2001), Dlx6 (Li et al., 2008), Msx2 (Cheng et al., 2003), Foxc2 (Kim et al., 2009),
and Twist (Hayashi et al., 2007) appear to play a crucial role.
Runx2, also known as Cbfa-1 (core binding factor α 1), is a runt-domain containing
TF, considered to be the master regulator of osteogenesis. Runx2 is expressed early during
skeleton formation in the developing embryo (Ducy et al., 1997) and Runx2 null mice
immediately die after birth due to a complete lack of bone formation (Komori et al., 1997).
Forced expression of Runx2 in preosteoblast cells results in increased expression of
osteoblast specific genes such as osteopontin, type-I collagen, and participate in
differentiation of MSCs into osteoblast like cells, both in vitro and in vivo (Ducy et al.,
1997; Zheng et al., 2004). In addition to specifying osteogenic fate, Runx2 inhibits
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chondrogenic and adipogenic differentiation of MSCs, which corroborates Runx2’s
cardinal function in osteogenesis (Kobayashi et al., 2000).
On the other hand, Osx is a zinc finger containing TF, exclusively expressed in
developing bones (Nakashima et al., 2002). Osx is essential for osteoblast differentiation
since Osx null mice exhibit normal physical morphology but lack bone formation
(Nakashima et al., 2002). Interestingly, Osx is a downstream regulator of Runx2 and Osx
expression is regulated by Runx2 (Nakashima et al., 2002). It has been proposed that Runx2
expression differentiates MSCs into bipotential preosteoblast progenitors that can
differentiate into osteoblast and chondrocytes (Nakashima et al., 2002). Osx expression
then direct the differentiation towards functional osteoblasts (Nakashima et al., 2002). In
fact, ectopic expression of Osx alone promotes osteogenic differentiation in MSCs (Wu et
al., 2007). However, Osx cannot induce terminal differentiation on its own, other regulators
are needed as well (Kurata et al., 2007).
Dlx3, 5, and 6 are homeodomain TFs that have been implicated in embryonic bone
formation and osteoblast differentiation (Zhao et al., 1994; Hassan et al., 2004; Li et al.,
2008). Dlx3 is highly expressed in osteoblasts and forced expression of Dlx3 in
osteoprogenitor cells induces expression of osteogenic genes (Hassan et al., 2004). Both
Dlx5 and Dlx6 are essential for craniofacial, axial, and appendicular skeletal development
and their ablation leads to postnatal lethality (Robledo et al., 2002). Just like Dlx3,
overexpression of Dlx5 accelerates osteoblast differentiation and stimulates increased
mineralization in preosteoblasts (Tadic et al., 2002). Interestingly, both Dlx3 and Dlx5
induce osteogenic differentiation by activating Runx2 expression (Hassan et al., 2006).
Overexpression of Dlx6 also strongly induces osteoblast differentiation (Li et al., 2008).
8

Interestingly, Dlx5 and Dlx6 are preferentially expressed in immature osteoblasts whereas
Dlx3 is highly expressed in differentiated osteoblast and osteocytes (Ryoo et al., 1997; Li
et al., 2008).
Msx2 is another homeobox TF of the Msx gene family that regulates osteogenesis
(Dodig et al., 1999). Induction of Msx2 expression in MSCs leads to osteogenic
differentiation, marked by significantly increased alkaline phosphatase activity and
calcification in the osteoblasts (Ichida et al., 2004). Msx2 expression also inhibits
adipogenesis by repressing key adipogenic TFs such as PPARγ, C/EBPα, C/EBPβ, or
C/EBPδ (Cheng et al., 2003; Ichida et al., 2004).
Foxc2, a member of the forkhead/winged helix TF family, also modulates
osteogenic differentiation of MSCs (Kim et al., 2009). Ectopic expression of Foxc2 induces
osteoblast differentiation in MSCs and preosteoblast cells by upregulating integrin β1,
which in turn improves osteoblast proliferation and differentiation (Park et al., 2011).
Twist is a basic helix-loop-helix (bHLH) TF which negatively regulates MSCs
osteogenesis (Hayashi et al., 2007). Twist overexpression inhibits bone morphogenetic
protein (BMP) signaling induced osteogenic differentiation of MSCs (Hayashi et al., 2007).
Twist repressive function depends on direct interaction and formation of multiprotein
repressive complex with Smad4 and histone deacetylase (HDAC) (Hayashi et al., 2007).
In contrast, adipogenic differentiation of MSCs is regulated by a combination of
TFs PPARγ (Tontonoz et al., 1994), C/EBPα (Rosen et al., 2002), C/EBPβ (Hamm et al.,
2001), C/EBPδ (Hishida et al., 2009), ADD1/SREBP1 (Tontonoz et al., 1993), KLF5
(Oishi et al., 2005), TLE3 (Kokabu et al., 2013), and CHOP10 (Batchvarova et al., 1995).
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Peroxisome proliferator activated receptor-γ (PPARγ), a nuclear hormone receptor,
is the master regulator of adipogenesis. PPARγ, particularly PPARγ2 is highly expressed
in adipocyte and forced expression PPARγ2 induces adipose differentiation in cultured
fibroblasts (Tontonoz et al., 1994) and transdifferentiate of myoblasts into adipocytes (Hu
et al., 1995). Ectopic PPARγ expression upregulates adipogenesis associated genes as well
as genes for fatty acid transporter, adipocyte lipid-binding protein (Bastie et al., 1999).
CAAT/enhancer binding proteins (C/EBPs) are another group of TFs that regulate
adipogenesis. These are highly expressed in liver and adipose tissue. Forced expression of
C/EBPs, particularly C/EBPβ stimulates adipogenic differentiation in multipotent MSCs
(Wu et al., 1995). C/EBPβ plays the key role during adipogenesis. Ectopic expression of
C/EBPβ in MSCs upregulates PPARγ which in turns stimulates expression of other
adipogenic factors (Hamm et al., 2001). Both C/EBPβ and C/EBPδ are typically expressed
early during preadipocyte differentiation (Tang et al., 2004). C/EBPβ then activates
C/EBPα and PPARγ. C/EBPα then induces terminal differentiation and maturation of
adipocytes by stimulating adipocyte-specific proteins (Tang et al., 2004; Hishida et al.,
2009).
Adipocyte commitment and differentiation dependent factor 1 (ADD1), also known
as sterol regulatory element-binding protein 1 (SREBP1) is a pro-adipogenic bHLH
containing TF that plays a key role during early adipogenic differentiation (Tontonoz et al.,
1993). Ectopic expression of ADD1 induces adipogenic differentiation in non-adipogenic
NIH3T3 cells and activates genes associated with fatty acid metabolism such as fatty acid
synthase (FAS) and lipoprotein lipase (LPL) (Kim and Spiegelman, 1996).
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ADD1/SREBP1 modulate adipogenesis by directing upregulate PPARγ expression (Fajas
et al., 1999)
Another zinc-finger TF associated with adipogenesis is Krüppel-like factor 5
(KLF5). KLF5 knockout mice are devoid of adipose tissues while forced expression of
KLF5 in MSCs induces adipogenic differentiation without other differentiation inducing
supplements (Oishi et al., 2005). KLF5 is typically activated early during adipocyte
differentiation, and its expression is highest during pre-adipocyte to adipocyte
differentiation (Oishi et al., 2005) (Mori et al., 2005). KLF5’s key function in inducing
adipogenesis is to upregulate PPARγ expression, which in turns coordinates terminal
differentiation of adipocytes (Mori et al., 2005).
Transducin like enhancer of split 3 (TLE3) is a dual functionality transcriptional
corepressor that also regulates adipogenesis. TLE3 promotes PPARγ expression and assists
PPARγ in transcriptional activation of adipogenic genes (Villanueva et al., 2011).
Meanwhile TLE3 inactivates Wnt signaling during adipogenesis by inhibiting TCL4
activation by b-catenin and prevents β-catenin dependent repression of adipocyte gene
expression (Villanueva et al., 2011).
CHOP10 (Gadd153) is a nuclear protein which negatively regulates
adipogenesis. At early stages of adipogenic differentiation, CHOP10 is expressed at an
elevated level, heterodimerizes with C/EBPα or C/EBPβ and prevents their transcriptional
activity (Batchvarova et al., 1995). However, at a later stage, when preadipocytes shift to
S phase, CHOP10 expression is repressed and C/EBPα or C/EBPβ is released from
CHOP10-mediated sequestration to transactivate adipogenic genes (Tang and Lane, 2000).
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Figure 2: Lineage pathway of osteogenic differentiation of mesenchymal stem cells
(MSCs). In response to osteogenic stimuli, MSCs differentiates into pre-osteoblast.
Preosteoblast then undergo a series of morphological and of epigenetic/transcriptional
remodeling governed by the key osteogenic transcription Factor, RUNX2, OSX, DLX5and
becomes terminally differentiated into osteoblasts and osteoclasts, respectively. Expression
of Runx2, Osx, Dlx5 and other osteogenic transcription factors is dynamically regulated at
different stages of differentiation (Kobayashi et al., 2000; Nakashima et al., 2002; Tadic et
al., 2002; Hassan et al., 2004; Hassan et al., 2006; Hayashi et al., 2007; Kurata et al., 2007;
Li et al., 2008; Karsenty et al., 2009; Javed et al., 2010; Fakhry et al., 2013; Bruderer et al.,
2014).
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Figure 3: Lineage pathway of adipogenic differentiation of mesenchymal stem cells
(MSCs) commence with MSC receiving adipogenic stimuli which induced adipogenic
commitment to the MSCs and differentiation to preadipocytes. Preadipocytes then undergo
terminal differentiation into mature adipocyte through a cascade of epigenetic and
transcriptional regulation, mainly governed by key adipogenic transcription Factor,
PPARγ, C/EBPα, C/EBPβ (Tontonoz et al., 1994; Batchvarova et al., 1995; Wu et al., 1995;
Tang and Lane, 2000; Hamm et al., 2001; Rosen et al., 2002; Tang et al., 2004; Farmer,
2006; Rosen and MacDougald, 2006; Hishida et al., 2009; Cristancho and Lazar, 2011;
Tang and Lane, 2012; Mota de Sa et al., 2017).
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2.3 Cellular microenvironment, and 3D cell culture:
Historically, most aspects of cellular structure, function, and differentiation have
been investigated using conventional 2D culture system – growing cells as a monolayer on
cell culture plates/dishes (plastic/glass). Such 2D approach has largely been instrumental
in uncovering fundamental basis of key cellular mechanisms such as replication, cell
division, cell cycle, cell fate determination etc. However, cellular activities such as cellextracellular matrix (ECM) interaction, cell fate determination due to cell-ECM
interaction, cell-cell interaction in stem cell niche or tumor, or cellular microenvironment
regulating gene expression or chromatin organization is very difficult to recapitulate in 2D
culture system, due to the intrinsic property of two dimension (Duval et al., 2017). To
overcome these hurdles, engineered scaffold or hydrogels that provides a 3D
microenvironment to the cells and closely mimic extracellular matrix have been designed
using natural or synthetic polymers that are either physically or chemically crosslinked
(Tibbitt and Anseth, 2009). Typically, the formulation of many hydrogels requires
incorporation of some natural extracellular matrix components such as laminin or collagen
in addition to the polymers (Matrigel); however, there are hydrogels that are solely
comprised of polymer or synthetic peptide (PuraMatrix). In addition to providing a 3D
microenvironment for the cells, hydrogels are biocompatible, highly permeable to oxygen,
nutrients, growth factors and supplement, able to exchange gas, and provide mechanical
support to the encapsulated cells (Tibbitt and Anseth, 2009; Youngblood et al., 2018).
Accumulating evidence suggest that cell’s behavior drastically changes when they
are maintained in 3D culture system, marked by changes in cell morphology, viability,
proliferation and differentiation potential, gene expression pattern etc., largely owing to
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the 3D microenvironment that allow cells to respond to biophysical and mechanical stimuli
as well the opportunity to interact with the extracellular matrix in all three dimensions, as
in vivo (Baker and Chen, 2012; Gauvin et al., 2012; Bonnier et al., 2015; Vining and
Mooney, 2017).
In addition to the 3D microenvironment provided by these hydrogels that allows
encapsulated cells to adapt to different morphology/geometric shape and function,
chemical/structural formulation of these 3D hydrogels as well as their intrinsic surface
topographies also affect cell function and/or differentiation. For instance, both Engler et
al., (2006) and Huebsch et al., (2010) have shown that MSCs preferentially undergo
osteogenesis when the stiffness of the hydrogel is intermediate to rigid whereas soft
matrices favor neurogenic commitment (Engler et al., 2006; Huebsch et al., 2010).
Together these observations suggest that compared to 2D culture system, 3D culture system
provides a more convenient and in vivo-like approach for studying cellular behavior and
cell fate commitment.
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Figure 4: Adhesive, topographical, mechanical, and soluble cues in 2D and 3D culture
system.
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2.4 Corning® PuraMatrix™ Peptide Hydrogel system for 3D cell culturing:
Corning® PuraMatrix™ Peptide Hydrogel is a peptide based synthetic matrix,
consisting of 1% (w/v) standard amino acids and 99% water. The structural basis of this
peptide hydrogel is the RAD16 oligopeptide, which consists of arginine (R), alanine (A),
and aspartic acid (D). Structurally RAD16 resembles the RGD (Arg-Gly-Asp) motif found
in many extracellular matrix proteins such as fibronectin. The RGD motif is recognized by
many proteins of the integrin family and this sequence has been found to play a crucial role
in cell adhesion (Ruoslahti, 1996).
Being composed of alternative hydrophilic and hydrophobic amino acids, these
peptides organize into β sheets in water (Zhang et al., 1995). In presence of physiological
buffer or medium containing millimolar amount of salts, this peptide spontaneously
organizes into membranous 3D matrices, exhibiting fibrous structure with average pore
size of 50-200 nm (Zhang et al., 1995; Holmes et al., 2000). Key advantages of Corning®
PuraMatrix™ Peptide Hydrogel over other hydrogels or 3D matrices such as Matrigel are
that PuraMatrix is completely synthetic, can be produced in larger quantities,
biocompatible, does not elicit immune response, and is devoid of animal products and
pathogens.
To this end, multiple stem/progenitor/primary cell types such as neural stem cells
(NSCs), and endothelial cells been used studied with Corning® PuraMatrix™ Peptide
Hydrogel (Narmoneva et al., 2005; Koutsopoulos and Zhang, 2013). However, MSCs have
not been studied with Corning® PuraMatrix™ Peptide Hydrogel yet. Therefore, one of the
aims of this study was to characterize BM-MSCs encapsulation, viability and
differentiation in Corning® PuraMatrix™ Peptide Hydrogel based 3D culture system.
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Figure 5: Structure of RAD16, and EAK16 oligopeptides. Here, A represents alanine; E =
glutamic acid; K is lysine; R stands for arginine; D is aspartic acid; G = glycine; S is serine;
P is proline. N- and C-termini end of the peptides is referred as N- and C-, - and + refer to
the negatively and positively charged amino acids, respectively.
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Figure 6: Proposed molecular model of the RAD16-II peptide which forms a stable βstrand with distinct polar and nonpolar sides in water or any other physiological solution
(Top). Molecular model depicting suggested interpeptide interaction due to the selfcomplementary feature of RAD16 (Bottom). Adopted from (Holmes et al., 2000).
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Chapter 3: Materials and Methods
3.1 Cell Culture:
Cryopreserved, passage 2 human bone-marrow derived mesenchymal stem cells
(BM-MSCs), collected from healthy, non-diabetic donors, were purchased from Lonza
(Catalog # PT-2501). These BM-MSCs express MSC-specific cell surface markers and can
differentiate into osteogenic, adipogenic, and chondrogenic lineages, corroborating bona
fide multipotency.
For experiments, BM-MSCs were seeded into T75 flasks at a density of 6,000
cells/cm2 using MSCs growth medium (500ml of basal medium supplemented with 25 ml
of fetal bovine serum, 5ml MSCs growth supplement, and 5ml penicillin/streptomycin
solution) from ScienCell Research Laboratories (# 7501), at a rate of 0.2ml/cm2 (i.e., 15ml
for T75 flask). At 80-90% confluency, BM-MSCs were sub-cultured using manufacture’s
protocol. MSCs growth medium were removed from the culture flasks and the cells were
washed with equal amount of PBS (Ca2+and Mg2+ free). After aspirating the PBS from the
flasks, adherent BM-MSCs were trypsinized using trypsin/EDTA solution (Lonza, # CC3232) at a concentration of 0.05ml/cm2 (i.e., 4ml per T75 flask) and the flasks were
incubated at 37°C for 5 minutes in a humidified 5% CO2 atmosphere. When ~ 90% of the
cells detached from the flask’s surface, the trypsin solution was neutralized with an equal
volume of MSC growth medium. The trypsinized cells were transferred to 15ml centrifuge
tubes and centrifuged for 5 minutes at 600 g. The supernatants were discarded, and the cell
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pellets were re-suspended in 1ml MSC growth medium. After calculating the cell
concentration, these were reseeded into new T75 flasks at the desired concentration and
were sub-cultured until passage 4. All experiments were done using passage 4 BM-MSCs,
unless mentioned otherwise.
3.2 3D Cell Culture with PuraMatrix Hydrogel:
3.2.1 BM-MSCs encapsulation in PuraMatrix Hydrogel:
For 3D cell cultures, BM-MSCs were encapsulated in Corning® PuraMatrix™
peptide hydrogel (Corning, # 354250) according to manufacturer’s instruction, optimized
accordingly.
The PuraMatrix hydrogel consists of 1% standard amino acids and 99% water.
Although a range of PuraMatrix hydrogel concentrations (i.e., 0.125% - 1%) have been
tested with BM-MSCs and adipose-derived MSCs, in our lab BM-MSCs appeared to be
more resilient and adaptable to 0.125% and 0.25% hydrogels, with 0.125% allowing the
most physiological adaptation and reorganization of the BM-MSCs within the matrix,
based on microscopic analysis. Therefore, all the biochemical, and histological
experiments were done with BM-MSCs encapsulated in 0.125% hydrogel unless
mentioned otherwise.
To encapsulate BM-MSCs in 0.125% hydrogel, the hydrogel stock solution (1%)
was sonicated in an ultrasonic bath for 30 minutes, to reduce its viscosity, and was diluted
to 2× concentration of 0.125% hydrogel solution with 20% sucrose. Meanwhile, passage 4
BM-MSCs were trypsinized and re-suspended in 10% sucrose solution at a concentration
of 1×106 cells/ml. Afterwards, the 2× concentrated 0.125% hydrogel solution were added
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to individual 1.5ml centrifuge tubes (125µL for 24-well plates and 25 µL for 96-well
plates) and an equal amount of cell-sucrose solution was mixed by gently pipetting up-anddown, followed by immediate plating into individual wells of non-treated cell culture
plates. Gelation of the hydrogel was induced immediately by gently adding MSC growth
medium in the corresponding wells. To neutralize the pH of the hydrogel with that of MSC
medium, the medium was changed twice within one hour of cell encapsulation. Medium
was changed every two days.
3.2.2 Cell recovery from 3D PuraMatrix Hydrogel for biochemical assays:
To recover BM-MSCs encapsulated 3D PuraMatrix hydrogel for biochemical
assays, the hydrogels were mechanically disintegrated by repeated up-and-down pipetting
inside the wells of the multi-well plate, followed by transfer of the hydrogel-medium
mixtures to 15ml centrifuge tubes. The 3D culture wells were washed again with an equal
volume of PBS (500µl/well for 24-well plates) and transferred to corresponding 15ml
tubes. The PBS-matrix-medium mixtures were centrifuged at 1000g for 5 minutes at 4°C.
The supernatants were discarded, with the remaining pellets consisting of cells and
PuraMatrix peptide fragments. The pellets were washed by re-dissolving in 2ml PBS and
centrifuged at 1000g for 5 minutes to re-pellet. These were resuspended in 500µl of
Trypsin/EDTA and incubated at 37°C for 5 minutes in a humidified 5% CO2 atmosphere.
Afterwards, 2ml of MSCs growth media was added to neutralize the trypsin, and the
mixture was centrifuged at 1000g for 5 minutes to re-pellet. The supernatants were
discarded, and the pellets were re-dissolved in 500µl PBS by repeated up-and-down
pipetting. The solutions were centrifuged, and the cells were collected as a pellet, that might
retain some residual peptide fragments which should not interfere with downstream
22

applications. Total RNA and protein extract were prepared from the cell pellets using
Trizol and RIPA buffer protocols mentioned for 2D cultured cells, described below.
3.3 Differentiation:
For differentiation experiments in 2D culture, passage 4 BM-MSCs were seeded
into 12-well plates (triplicates for each condition: control, osteogenesis, and adipogenesis)
at a density of 6,250 cells/cm2, maintained in MSC growth medium (1ml per well). At
~90% confluency, osteogenic and adipogenic differentiation were induced by changing
MSCs growth medium to osteogenic and adipogenic induction media, respectively.
Osteogenic induction medium consists of MSCs growth medium supplemented with 0.1
µM dexamethasone, 0.2 mM l-ascorbate, and 10 mM glycerol-3-phosphate whereas
adipogenic medium contains 1 µM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine
(IBMX), 100 µM indomethacin, and 10 µg/ml insulin supplemented in MSCs growth
medium. For control, cells were maintained in MSCs growth medium only. All media were
changed every 3-4 days.
For differentiation experiments in 3D hydrogel, 1 × 106 cells/ml passage 4 BMMSCs were encapsulated in 0.125% PuraMatrix hydrogel and were seeded in 24-well untreated plates. After 3 days post-encapsulation, to allow cells to adapt and reorganize within
the hydrogel matrix, differentiation was induced by changing the MSCs growth medium to
osteogenic and adipogenic induction media. The media were replaced every 2 days.
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3.4 Staining:
3.4.1

Alizarin Red S Staining
Osteogenic differentiation of MSCs is characterized by deposition of calcium in

pre/mature osteoblasts. Alizarin Red S staining is typically used to visualize calcium
deposits following osteogenic differentiation, through the complexation of this dye with
the calcium molecules via its sulfonic acid and/or hydroxy groups (Birmingham et al.,
2012; Kraus et al., 2016).
For Alizarin Red S Staining, passage 4 BM-MSCs were grown on glass coverslips
placed in 12-well plates in 2D cultures or 8-well chamber slides for 3D encapsulation. After
medium aspiration, the cells were washed twice with PBS and fixed with 4%
paraformaldehyde in PBS for 15 minutes at room temperature. The fixative was then
removed, and the cells were washed 3 times with de-ionized (DI) H2O. Afterwards, 1ml of
Alizarin Red S Staining Solution (300µl for chamber slides) (ScienCell Research
Laboratories, Inc., # 0223) was added to each well and the plates were incubated for 30
minutes at room temperature. Following incubation, the staining solution was carefully
aspirated, and the cells were washed 5× with DI H2O for 1 minute each to remove unbound
and excess stain. Afterwards, the coverslips were mounted on glass slides using ProLong™
Diamond Antifade mounting medium (Invitrogen, # P36965) and the slides were dried,
sealed with nail polish, and stored in the dark at 4°C until imaged.
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3.4.2

Oil Red O Staining:
Adipogenic differentiation is generally associated with deposition of lipid or fat

deposits in pre/mature adipocytes. To visualize such lipid or fat droplets in cells or tissue,
Oil Red O staining is typically used (Kraus et al., 2016).
For Oil Red O staining, passage 4 BM-MSCs that were grown on glass coverslips,
placed in 12-well plates for 2D culture system or 8-wells 3D chamber slides for 3D cell
culture, were fixed with 4% paraformaldehyde in PBS, as mentioned above. After the
fixative was removed, the cells were washed 3× with DI H2O, and incubated with 1ml of
working Oil Red O staining (300µl for 3D slides) solution per well for 25 minutes. Working
Oil Red O solution is prepared from a stock solution (ScienCell Research Laboratories,
Inc., # 0843) by diluting with DI H2O in a 3:2 ratio and filtered using a 0.2µm syringe
filter. After incubating for 25 minutes, the staining solution were removed, and the cells
were washed 5× with DI H2O. Afterwards, the coverslips were mounted on glass slides and
stored at 4°C until imaged.
3.5 Immunohistochemistry:
Passage 4 BM-MSCs were grown and maintained on round coverslips, placed in
12-well 2D plates or 8-well 3D slides until confluency. For immunohistochemistry,
growth/differentiation medium was gently removed from the plates and cells were washed
once with PBS at room temperature for 1 minute. Afterwards, the cells were fixed with
1ml/well of 4% paraformaldehyde in PBS for the 12-well plate or 300µl/well for the 8-well
3D slides, for 15 minutes at room temperature. Then the fixative was carefully removed,
and the plates were washed with PBS for 1 minute. Fixed cells were then permeabilized by
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adding 1 ml of buffer (i.e., 0.5% Triton-X100 in PBS) per well and incubated for 5 minutes
at room temperature. Afterwards, the permeabilization buffer was removed from the plates
and the plates were washed twice with PBS for 1 minute. Permeabilized cells were then
incubated with 250µl of 100nM Acti-stain™ 488 Phalloidin in PBS and were incubated
for 30 minutes at room temperature in the dark. Following the phalloidin incubation, the
phalloidin-PBS solution was removed from the plates and these were washed 3× with PBS
for 1 minute. For counterstaining the nucleus/DNA, 300µl of DAPI (NucBlue® Fixed Cell
ReadyProbes® Reagent) in PBS was added to each coverslip and incubated at room
temperature for 5 minutes. Afterwards, the DAPI-PBS solution was removed from the
plates and these were washed 3× with PBS for 1 minute. Following washing, the coverslips
were carefully mounted on glass slides using Prolong Gold mounting medium. Afterwards,
the coverslips were dried and sealed with nail polish, and stored in the dark at 4°C until
imaged.
3.6 RNA Extraction, cDNA synthesis:
For gene expression analysis, RNA was isolated from confluent, passage four BMMSCs grown in 12-well or 3D hydrogels in 24-well plates. Growth/differentiation medium
was removed from each well and the cells were washed once with ice-cold PBS.
Afterwards, the cells were then lysed by adding the appropriate amount of TRIzol™
Reagent (15596026). Trizol-lysed cell samples were homogenized, and the RNA, DNA,
and proteins were separated in different layers by addition of chloroform and subsequent
centrifugation at 12,000g for 15 minutes at 4°C. The RNA phase was carefully transferred
into new 1.5ml centrifuge tube and then precipitated with isopropanol. The precipitated
RNA was washed twice with 75% ethanol to remove any contaminant, and then dissolved
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in RNAse-free water. RNA concentration and quality were analyzed using the NanoDrop
1000 spectrophotometer according to manufacturer’s instruction and the integrity of RNA
samples were analyzed using 8% agarose gel electrophoresis.
3.7 Gene Expression Analysis (qRT-PCR):
For gene expression analysis, single stranded cDNAs were prepared from 200ng of
total RNA from all 2D and 3D cell samples using SuperScript® III First-Strand Synthesis
SuperMix (Thermo Fisher Scientific, # 18080400) following manufacturer’s protocol.
Resultant cDNA samples were then diluted 5-fold to use in quantitative real time
polymerase chain reaction (PCR) or qRT-PCR experiments, performed using Applied
Biosystem’s Step One plus instrument and Power SYBR™ Green PCR Master Mix (#
4367659), according to manufacturer’s protocol. The primer sets for the analyzed genes
are given below:
Table 1: List of primers for osteogenic and adipogenic transcription factors.
Forward primer

CAACGACCACTTTGTCAAGC

Reverse primer

TTCCTCTTGTGCTCTTGCTG

Forward primer

GGAGTGGACGAGGCAAGAGTTT

Reverse primer

AGCTTCTGTCTGTGCCTTCTGG

OSTERIX/SP7

Forward Primer

CCTCTGCGGGACTCAACAAC

(Osx)

Reverse Primer

AGCCCATTAGTGCTTGTAAAGG

Forward primer

TTCTCGGTCTGGAGGATGGA

Reverse primer

AATGACATCTAGGTCTCCGGC

Forward primer

CCTATTGACCCAGAAAGCGATT

GAPDH

RUNX2

TWIST1
PPARγ
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Reverse primer

CATTACGGAGAGATCCACGGA

Forward primer

GCAAACTCACCGCTCCAATG

Reverse primer

GGAAGGAGGCAGGAAACCTC

Forward Primer

GGAAACAGAGTGGTCATTCCC

Reverse Primer

CTGCTTGAGCCGTTCATTCTC

C/EBPα

CHOP10/DDIT3

3.8 Protein Extraction and Quantification:
3.8.1 Protein Extraction from BM-MSCs:
Total protein extracts from the cultured BM-MSCs were prepared using RIPA Lysis
and Extraction Buffer (Thermo Fisher Scientific, # 89900) supplemented with Halt™
Protease and Phosphatase Inhibitor cocktail (100X) (Thermo Fisher Scientific, # 78442)
with a final concentration of 1X. To extract total proteins, MSCs growth medium were
aspirated from BM-MSCs cultured in 12-well plates or 24-well plates (3D culture), and the
cells were washed twice with cold PBS (1ml/well in 12-well plate). After aspirating the
PBS, 250µl of cold RIPA buffer containing the inhibitors were added to each well and the
plates were placed on ice for 15 minutes, swirling every 3-5 minutes. After incubating in
the ice, cells in the RIPA buffer were scraped from the plates using cell scrapers and the
lysate was pipetted to homogenize the cells prior to transferring the lysates into 1.5ml
centrifuge tubes. The cell lysates were further homogenized by rigorously vortexing for 1
minute. Afterwards, the protein lysate was sonicated for 1 minute to facilitate complete
dissolution of cell wall and homogenization of the proteins. Sonicated cell extracts were
then centrifuged at 14,000 g for 15 minutes at 4°C. After centrifugation, the protein
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supernatants were transferred to fresh 1.5ml tubes and store at -80°C until used for protein
quantification and SDS-PAGE/Western blot experiments.
3.8.2

Protein Quantification by Bradford Assay:
Protein samples were quantified using Bradford Protein assay, utilizing Coomassie

Plus (Bradford) Assay Kit (Thermo Scientific, # 23236). Protein samples were thawed on
ice and 50µl of protein samples were mixed with 1,500µl of Coomassie Plus reagent by
inverting multiple times and incubating for 10 minutes at room temperature. Afterwards,
the protein-Coomassie reagent mixture were transferred to disposable plastic cuvettes and
their absorbance was measured at 595nm, using H2O-Coomassie mixture as blank. The
absorbances obtained from the samples were used to calculate corresponding protein
concentration, using the standard equation obtained from the absorbance of bovine serum
protein (BSA) dilutions (2,000µg/mL, 1,500µg/mL, 1,000µg/mL, 750µg/mL, 500µg/mL,
250µg/mL, 125µg/mL, and 25µg/mL).
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Table 2: BSA dilutions and their absorbance for protein standard curve and Bradford
quantification.
Standards

Absorbance

Sample 2000_1

1.509

Sample 2000_2

1.657

Sample 2000_3

1.499

Sample 1500_1

1.388

Sample 1500_2

1.358

Sample 1500_3

1.321

Sample 1000_1

1.216

Sample 1000_2

1.154

Sample 1000_3

1.129

Sample 750_1

0.964

Sample 750_2

0.951

Sample 750_3

0.947

Sample 500_1

0.656

Sample 500_2

0.663

Sample 500_3

0.701

Sample 250_1

0.409

Sample 250_2

0.368

Sample 250_3

0.327

Sample 125_1

0.211

Absorbance (Avg.)

Concentration (ug/ml)

1.555

2000

1.356

1500

1.166

1000

0.954

750

0.673

500

0.368

250
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Sample 125_2

0.172

Sample 125_3

0.189

Sample 25_1

0.03

Sample 25_2

0.047

Sample 25_3

0.03

0.191

125

0.036

25
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Figure 7: Protein standard curve generated from multiple dilution of bovine serum
albumin (BSA) and their corresponding absorbance at 595nm. The equation from this
curve is used quantify protein concentration of different samples.
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3.9 SDS-PAGE Gel Electrophoresis and Western Blotting:
SDS-PAGE gel electrophoresis was used to separate the proteins based on their
size. Thirty micrograms of total protein from all the protein samples were mixed in equal
amounts of 2× protein loading buffer (Lammieli buffer) and were heated for 10 minutes at
65°C prior to loading into 10% Mini-PROTEAN® TGX™ Precast protein gels (Bio Rad,
# 4561034). Gel tanks were filled with 1× running buffer (25mM Tris, 190mM Glycine,
0.1% SDS) and run for 1 hour at 110V. The proteins were transferred to a methanolactivated PVDF membrane using Bio Rad’s fast transfer system. Following the transfer,
the membranes were blocked with 5% BSA in TBST (TBS with 0.1% Tween 20) for 1
hour at room temperature. After blocking, the membranes were incubated with primary
antibodies at 1:1,000 dilution, overnight at 4°C. Next day, the primary antibodies were
removed, and the membranes were washed 3× with TBST for 10 minutes each, and then
incubated with equal volumes of horseradish peroxidase (HRP)-tagged secondary
antibodies in TBST at 1:2,000 dilution for 1 hour. After secondary antibody incubation,
the membranes were washed 3× with TBST 10 minutes each and incubated for 5 minutes
with Clarity™ Western ECL Substrate (# 1705060) before imaging.
All the membranes were stripped before incubating with primary antibodies. For
stripping, imaged membranes were incubated in Restore™ Western Blot Stripping Buffer
(Thermo Fisher Scientific, # 21059) for 15 minutes with rocking at room temperature.
Stripped membranes were washed 3× for 10 minutes each and then blocked again, prior to
incubating with next primary antibody.
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Table 3: Concentration of primary and secondary antibodies for western blotting.
Antibody

Dilution

RUNX2 (Primary)

1:1000

PPARy (Primary)

1:1000

GAPDH (Primary)

1:1000

Anti-Goat HRP tagged Secondary Antibody

1:2000
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3.10 Cell Viability/MTS Assay:
MTS cell proliferation/viability assay experiments were performed to evaluate cell
viability of BM-MSCs encapsulated in PuraMatrix 3D hydrogel. Passage 4 BM-MSCs
were encapsulated in 0.125% or 0.25% PuraMatrix with seeding density of 1×106 and
2×106 cells/ml in 96-well plates. Following encapsulation and adaptation of cells to the
hydrogels, cells were treated with 20µl of CellTiter 96® AQueous One Solution Reagent
(Promega, # G3582) and incubated for 2.5 hours at 37°C in a humidified, 5% CO2
atmosphere. Following incubation, the absorbance of the plates was measured at 490nm
using a 96-well plate reader. MTS assays were done at Day 0, Day 3, and Day 7 of BMMSC encapsulation.
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Chapter 4: Characterization of BM-MSCs encapsulation in Corning®
PuraMatrix™ Peptide Hydrogel.
4.1 Introduction:
Corning® PuraMatrix™ Peptide Hydrogel is a novel 3D culture system, consisting
of 1% standard amino acids and 99% water. Unlike other polymer or hydrogel-based 3D
culture system, PuraMatrix is completely synthetic, can be produced in large quantities,
and is not known to elicit an immune response (Zhang et al., 1995). Largely, these features
make PuraMatrix™ Peptide Hydrogel system an attractive tool for making cellular
matrices for tissue engineering and regenerative medicine. To this end, multiple
stem/progenitor cell types such as fetal human neural stem cells (hNSCs) (Thonhoff et al.,
2008), rat liver progenitor cells (Semino et al., 2003), human microvascular endothelial
cells (MVEC) (Narmoneva et al., 2005) and others have been tested for their ability to
adapt and differentiate when encapsulated in PuraMatrix™ Peptide Hydrogel. However,
BM-MSCs with PuraMatrix™ Peptide Hydrogel have not been characterized. Therefore,
we sought to evaluate the ability of BM-MSCs to proliferate and differentiate when
encapsulated in PuraMatrix™ Peptide Hydrogel.
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4.2 Results:
4.1.1 BM-MSC viability in PuraMatrix™ Peptide Hydrogel with varying peptide
concentration:
Stock PuraMatrix™ Peptide hydrogel consists of 1% (w/v%) peptide and 99%
water, making it an 1% hydrogel system. Initially, we tested encapsulation of passage 4
BM-MSCs in 1%, 0.75%, 0.5%, 0.25%, and 0.125% peptide hydrogels; however, using
bright field microscopy based morphological assessment, we found that BM-MSCs tend to
be most adaptable to 0.125% and 0.25% peptide hydrogel, 0.125% hydrogel allowing them
to reorganize themselves the most to interact with neighboring cells. Using MTS based cell
viability assay, we have found that following post-encapsulation (immediately), viability
of passage 4 BM-MSCs with a seeding density of 0.1×106cells/ml (2500 cells/well of a 96
well plate) in 0.125% peptide hydrogel is about 91% (91%±.03), compared to 2D cultured
BM-MSCs (Figure 8). However, viability of BM-MSCs following encapsulation appears
to be dependent on initial cell seeding density. With a seeding density of 0.2×106cells/ml
(2500 cells/well of a 96 well plate), viability of BM-MSCs encapsulated in 0.125%
PuraMatrix peptide hydrogel improves from 91% to 98% (98±.08) (Figure 8). Therefore,
we propose that high seeding density is favorable for efficient encapsulation of BM-MSCs
in PuraMatrix peptide hydrogel.
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Figure 8: Viability of BM-MSCs encapsulated in 0.125% PuraMatrix peptide hydrogel.
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4.1.2 Actin remodeling of BM-MSC encapsulated in Corning® PuraMatrix™ Peptide
Hydrogel:
Although different cell types are characterized by their unique cellular shape and
morphology, one key element of cellular architecture that plays a crucial role in
determining cellular shapes and cellular motility is the actin filament. Actin and its
accessory proteins are collectively referred as actin cytoskeleton. Due the cardinal function
of actin cytoskeleton controlling cell shape and morphology, any cellular shape and/or
morphologic assessment is usually determined by staining the actin with fluorescently
labeled antibody or phalloidins conjugates and counterstaining the nucleus with DAPI.
Historically, MSCs or stromal cells have been considered to have fibroblast-like
morphology which is represented by heir spindle shape. Part of this morphology and shape
could also be attributed to the way MSCs have been cultured – as a monolayer in cell
culture dishes. In the 2D cell culture plates/dishes, adherent MSCs attach to the plate
surface and continue to proliferate/divide while being attached to the plate surface
horizontally. Such attachment organizes the actin filaments in a flat elongated orientation
known as stress fiber (Figure 10A). We reasoned that in a 3D microenvironment where
cells can freely move within the matrix and can organize themselves, MSCs will adopt a
different cellular organization and shape. As anticipated, undifferentiated passage 4 BMMSCs encapsulated in 0.125% peptide hydrogel appeared to be round in shape and
reorganize their actin cytoskeleton to interact with their neighbors and possess more
lamellipodia and filopodia compared to their 2D grown counterparts (Actin staining was
done 3 days post-encapsulation) (Figure 10B). We speculate that, in addition to new
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structural organization, hydrogel-encapsulated BM-MSCs may behave and express
cytokines/chemokines differently.
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Figure 9: Bright-field microscopy analysis of passage 4 BM-MSCs cultured in (A) 2D
culture plated and (B) encapsulated in 3D PuraMatrix peptide hydrogel (Scale bar = 50µm).
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Figure 10: Morphological analysis of (A) 2D and (B) 3D culture BM-MSCs (B) using
immunohistochemistry. Actin filament (green) and nucleus (blue) of BM-MSCs were
stained using alexa fluor 488 phalloidin and DAPI respectively, showing the differential
actin organization of BM-MSCs in 2D and 3D culture system. In 2D culture system, BMMSCs (Scale bar = 50µm).
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Chapter 5: Transcriptional analysis of key osteogenic and adipogenic
transcription factor during BM-MSC differentiation in 2D and 3D culture
systems.

5.1 Gene expression analysis osteogenic differentiation of BM-MSCs in 2D and 3D
culture:
5.1.1 Introduction:
Multipotency of BM-MSCs enables them to differentiate into mesodermal lineages
such as osteogenic, adipogenic, and chondrogenic lineages. We were particularly interested
in osteogenesis and adipogenesis of BM-MSCs because commitment to these lineages is
reciprocally regulated by BM-MSCs throughout animal development and in certain disease
conditions. Upon exposure to osteogenic stimuli (hormones, growth factors, etc.), BMMSCs start to specialize into pre-osteoblast progenitor cells and this commitment restricts
their differentiation to adipogenic or chondrogenic lineages (Javed et al., 2010; Fakhry et
al., 2013). Pre-osteoblast cells differentiate into immature osteoblast as a result of elevated
expression of Runx2, Osx, and Dlx5. The transition of immature to mature osteoblast,
however, is inhibited by Runx2 (Komori, 2006; Karsenty et al., 2009). At this time point,
other osteogenic transcription factors such as Msx, and Dlx3 play key roles and allow
immature osteoblast to become mature osteoblast. We sought to explore how Runx2, Osx,
and Twist expression is differentially modulated during the course of osteogenic
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differentiation, at different time point. We also wanted to evaluate if growth in a 3D
microenvironment affects expression pattern of these transcription factors.
5.1.2 Results:
At first, we sought to evaluate if maintenance of undifferentiated hBM-MSCs in
PuraMatrix based 3D hydrogel, in contrast to 2D culture, have any effect on GAPDH as
well as osteogenic (RUNX2, OSX, and TWIST1) and adipogenic transcription factors
(PPARγ, C/EBPα, and CHOP10).
We have found that besides OSX and C/EBPα, expression of GAPDH, RUNX2,
TWIST1, PPARγ, and CHOP10 significantly (p <0 .00001) decreases when hBM-MSCs
are encapsulated in 0.125% PuraMatrix peptide hydrogel (Figure 11). On average, in 3D
culture GAPDH expression could be detected after 5 cycle (5.3±0.15) (p < 0.00001) over
2D, RUNX2 about 4 cycle (4.05±0.44) (p < 0.00001), TWIST1 about 6 cycle (5.73±0.30)
(p < 0.00001), PPARγ about 2 cycle (1.94±0.14) (p < 0.00001), and CHOP10 about 6 cycle
(6.35±0.34) (p < 0.00001).
To analyze the relative expression of RUNX2, OSX, and TWIST1 during
osteogenic differentiation of BM-MSCs, we collected total RNAs from 2D and 3D cultured
cell samples at Day 0 (undifferentiated control), Day 3, Day 7, Day 14, and Day 21 of
differentiation. cDNA made from the total RNA samples were used in performing
quantitative PCR (qPCR) for analyzing gene expression. Gene expression data sets were
analyzed and fold change were calculated using delta delta CT method (Livak and
Schmittgen, 2001). Expression data were normalized to GAPDH expression.
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Compared to the control undifferentiated BM-MSCs (Day 0), RUNX2 expression
increased significantly about 1.8 fold (1.81±.5) (p = 0.04) at Day 3, about 1.86 fold
(1.86±0.54) (p= 0.05) at Day 7, about 2.03 fold (2.03±0.56) (p = 0.04) fold at Day 14, and
about 3.6 fold (3.61± 0.41) (p = 0.003) fold at Day 21 of osteogenic differentiation, in 2D
culture system (Figure 12). Considering Runx2 expression is expected to increase over the
course of differentiation, particularly when MSC commits to pre-osteoblast progenitors
and forms immature-osteoblast, our RUNX2 expression profile is consistent with
established tenet.
In contrast to 2D system, RUNX2 expression did not significantly increase
(1.09±0.60) (p = 0.74) at Day 3 relative to Day 0 (undifferentiated control) or change
(.90±0.48) (p = 0.62) over control at Day 7 suggesting basal level of expression up to Day
7 of differentiation. However, RUNX2 expression significantly increased, about 3.4 fold
(3.38±0.46) (p = 0.004) over control at Day 14, and 8.9 (8.94±0.95) (p = 0.01) fold
increment at Day 21 of osteogenic differentiation in 3D culture (Figure 12). Although
RUNX2 expression in 3D culture system follow same pattern of expression as the 2D
culture system and the expression profile reported by other studies, any fold change
difference between 2D and 3D culture system, at different time point during differentiation
may largely be due to the difference in metabolic and morphological changes associated
with BM-MSCs adapting to a 3D microenvironment.
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Figure 11: Differential expression of GAPDH, RUNX2, OSX, TWIST, PPARγ, C/EBPα,
and CHOP10 transcription factors between undifferentiated hBM-MSCs from 2D and 3D
PuraMatrix hydrogel.
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Figure 12: Differential expression of RUNX2 during osteogenic differentiation of BMMSCs in 2D and PuraMatrix based 3D culture. qPCR analysis shows the relative change
in RUNX2 expression (relative to undifferentiated hBM-MSCs) at Day 3, Day 7, Day 14,
and Day 21 of differentiation, normalized to GAPDH. n = 3 and error bars = standard error
of the mean. "*" means p< 0.05, "**" means p< 0.01, "***" means p< 0.001, and "****"
means p<0.0001.
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For Osterix (OSX), OSX expression significantly increased about 13.3 fold (13.27±
0.67) (p = 0.01) at Day 3 of osteogenic differentiation in 2D culture system, compared to
undifferentiated control (Day 0) BM-MSCs (Figure 13). However, OSX’s expression
decreased about ~12 fold down to basal level (1.14± 0.21) (p = 0.3) at Day 7 and continued
to be expressed slightly elevated or basal level, over control, at Day 14 (1.55 ± 0.72) (p =
0.3) and Day 21 of osteogenic differentiation (1.58± 0.47) (p = 0.13) in 2D culture system
(Figure 13). This observation suggests that OSX is an early osteogenic regulator,
functioning at the early stage of differentiation.
Interestingly, in 3D culture system, OSX expression significantly decreased about
5-fold (0.18± 0.69) (p = 0.02) at Day 3 of osteogenic differentiation in 2D culture system,
compared to control (Day 0, undifferentiated) BM-MSCs and continued to decrease about
20-fold (.05± 0.47) (p = 0.0007) over control at Day 7 (Figure 13). OSX started to increase
after Day 7, and at Day 14, OSX expression increased about 2.8 fold (2.77 ± 0.88) (p =
0.09) and about 5.4 fold (5.43± 0.52) (p = 0.006) over control at Day 21 of osteogenic
differentiation (Figure 13).
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Figure 13: Differential expression of OSX during osteogenic differentiation of BM-MSCs
in 2D and PuraMatrix based 3D culture. qPCR analysis shows relative change in OSX
expression (relative to undifferentiated hBM-MSCs) at Day 3, Day 7, Day 14, and Day 21
of differentiation, normalized to GAPDH. n = 3 and error bars = standard error of the mean.
"*" means p< 0.05, "**" means p< 0.01, "***" means p< 0.001, and "****" means
p<0.0001.
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Considering TWIST1 is a negative regulator of MSCs osteogenesis, we expected
to see reduction of TWIST1 at the early stage of differentiation and continued repression or
basal level expression during the differentiation of BM-MSCs into mature osteoblasts.
In 2D culture system, TWIST1 expression significantly increased about 9.1 fold
(9.09 ± 0.94) (p = 0.01) at Day 3 of osteogenic differentiation in 2D culture system,
compared to Day 0 BM-MSCs (undifferentiated control) (Figure 14). However, at Day 7
TWIST1 expression decreased about ~2 fold to 7.9 fold (7.90± 0.58) (p = 0.001) over
control and was only trending to be lower than control at Day 14 (0.67 ± 0.61) (p = 0.19)
and about the same over control at Day 21 (0.93±0.48) fold (p = 0.74) of osteogenic
differentiation, in 2D culture system (Figure 14).
Surprisingly, in 3D culture system, TWIST expression had a trend towards
decreased expression over control (about 1.6 fold) (0.64± 1.03) (p = 0.3) at Day3 of
osteogenic differentiation in 2D culture and continued to trend towards a decrease of 2.2
fold (.46± 0.10) (p = 0.2) over control at Day 7. Interestingly, TWIST started to increase
after Day 7, and at Day 14, TWIST expression increased about 1.7 fold (1.71± 1.12) (p =
0.31) over control, and about 1.9 fold (1.89± 1.03) (p = 0.2) at Day 21 of osteogenic
differentiation (Figure 14). Considering TWIST did not change significantly during the
course of osteogenic differentiation in 3D culture system, it is possible that TWIST is
expressed at basal level and does not undergo significant down regulation in 3D culture
system.

50

Figure 14: Differential expression of TWIST during osteogenic differentiation of BMMSCs in 2D and PuraMatrix based 3D culture. qPCR analysis shows relative change in
TWIST expression (relative to undifferentiated hBM-MSCs) at Day 3, Day 7, Day 14, and
Day 21 of differentiation, normalized to GAPDH. n = 3 and error bars = standard error of
the mean. "*" means p< 0.05, "**" means p< 0.01, "***" means p< 0.001, and "****"
means p<0.0001.
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5.2 Gene expression analysis of adipogenic differentiation of BM-MSCs in 2D and 3D
culture:
5.2.1 Introduction:
Adipogenesis of MSCs or adipo-progenitor cells begins with commitment towards
adipogenic lineage in response to adipogenic stimuli (hormones, growth factors, etc.).
Adipogenic stimuli activate a series of signal transduction cascades that lead to high level
expression of ERG2, and CREB, and expression of these early adipogenic activators
initiates adipogenic commitment in MSCs or adipogenic progenitors (Karsenty et al., 2009;
Javed et al., 2010). Following commitment, terminal differentiation takes place once
C/EBPβ is activated and expressed at high level followed by C/EBPγ expression at the
early stage of terminal differentiation. Activated C/EBPβ then activates C/EBPα, which
then activates PPARγ. PPARγ and C/EBPα have an inbuilt auto regulatory feedback
system where activated PPARγ autoactivates itself as well as C/EBPα (Javed et al., 2010;
Fakhry et al., 2013; Bruderer et al., 2014). C/EBPα also continues to promote PPARγ
expression until the pro-adipocytes differentiate into mature adipocytes. In addition to
terminally differentiating into mature adipocytes, both PPARγ and C/EBPα play key role
in maintaining mature adipocyte identity (Fakhry et al., 2013; Bruderer et al., 2014).
To analyze gene expression pattern of PPARγ, C/EBPα, and CHOP10 during
adipogenesis of BM-MSCs, total RNAs from cell samples at Day 0 (undifferentiated
control), Day 3, Day 7, Day 14, and Day 21 of differentiation was isolated, and cDNA was
made to perform quantitative PCR (qPCR). Gene expression analysis was performed using
delta delta CT method (Livak and Schmittgen, 2001). Expression data were normalized to
GAPDH expression.
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5.2.2 Results:
Compared to control (Day 0, undifferentiated) BM-MSCs, PPARγ expression
significantly increased, about 9.9 fold (9.85± 0.93) (p = 0.02) at Day 3 but decreased to
about 5.7 fold (5.72± 0.44) (p = 0.002) over control at Day 7. However, PPARγ expression
again increased about 11.1 fold (11.11± 1.25) (p = 0.04) fold at Day 14, and about 29 fold
(28.85±0.55) (p = 0.0009) at Day 21 of adipogenic differentiation, over control, in 2D
culture (Figure 15).
Interestingly, in 3D culture system, PPARγ expression increased about 41 fold
(40.82± 1.70) (P = 0.03) over control at Day 3, but markedly downregulated to
basal/control level (0.96 ± 2.36) (p = 0.965456918) at Day 7 of adipogenic differentiation
(Figure 15). However, PPARγ expression again trended toward an increase of about 5.6
fold (5.56 ± 2.72) (p = 0.3) at Day 14, and about 8 fold (7.98 ± 1.56) (p = 0.07) over control
at Day 21 of differentiation, in 3D culture (Figure 15). Although expression pattern of
PPARγ in 3D culture correlates with that of in 2D culture, the relative difference in the fold
change is due to different unique gene expression program active in 3D culture BM-MSCs
upon encapsulation.
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Figure 15: Differential expression of PPARγ during adipogenic differentiation of BMMSCs in 2D and PuraMatrix based 3D culture system. qPCR analysis shows relative
change in PPARγ expression (relative to undifferentiated hBM-MSCs) at Day 3, Day 7,
Day 14, and Day 21 of differentiation, normalized to GAPDH. n = 3 and error bars =
standard error of the mean. "*" means p< 0.05, "**" means p< 0.01, "***" means p< 0.001,
and "****" means p<0.0001.
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Expression of C/EBPα increased significantly, about 897 fold (897.44± 1.16) (p =
0.0002) at Day 3 of adipogenic differentiation, compared to control (Day 0,
undifferentiated) in 2D culture (Figure 16). However, C/EBPα expression decreased to
about 9 fold increment over control (8.93± 1.08) (p = 0.01) at Day 7 of differentiation and
then decreased to 6.1 fold over control (6.09±1.04) (p = 0.02) at Day 14 of differentiation.
However, C/EBPα expression again significantly upregulated, about 21 fold over control
(21.01±0.94) (p = 0.009) at Day 21 of differentiation (Figure 16).
Unexpectedly, in 3D culture system, C/EBPα expression significantly decreased
about 6.6 fold over control (0.15±1.71) (p = 0.05) at Day 3 of differentiation but returned
to basal level (1.24±3.36) (p = 0.9) over control at Day 7 of differentiation (Figure 16).
However, C/EBPα expression continued to be expressed at basal level (.60±2.87) (p = 0.7)
at Day 14 and Day 21 (0.76±2.86) (p = 0.7) of differentiation. Considering C/EBPα is a
direct transcriptional target of PPARγ (with an inbuilt auto-regulatory feedback system that
promotes both of these transcription factors expression), low PPARγ expression between
Day 3 and Day 14 of adipogenic differentiation in 3D culture might lead to basal level
expression of C/EBPα at that time period.
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Figure 16: Differential expression of C/EBPα during adipogenic differentiation of BMMSCs in 2D and PuraMatrix based 3D culture system. qPCR analysis shows relative
change in C/EBPα expression (relative to undifferentiated hBM-MSCs) at Day 3, Day 7,
Day 14, and Day 21 of differentiation, normalized to GAPDH. n = 3 and error bars =
standard error of the mean. "*" means p< 0.05, "**" means p< 0.01, "***" means p< 0.001,
and "****" means p<0.0001.
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CHOP10 is a negative regulator of adipogenesis and have been found to be
expressed at elevated level at undifferentiated MSCs and early stage of differentiation in
and pre-adipocyte cell lines. Therefore, we expected to see suppression of CHOP10
expression following differentiation.
In 2D culture system, CHOP10 expression significantly downregulated about 3
fold (0.33±0.68) (p = 0.03) at Day 3, and about 2.6 fold (0.39±.92) (p = 0.09) at Day 7 of
differentiation, over control (Day 0, undifferentiated BM-MSCs) (Figure 17). CHOP10
expression continued to decrease about 4.8 fold over control (0.21±0.62) (p = 0.005) at
Day 14 and about 2.3 fold (0.43±0.58) (p = 0.03) at Day 21 of differentiation (Figure 17).
Surprisingly, in 3D culture system, CHOP10 expression did not change (1.23
±3.01) (p = 0.9) at Day 3 (control undifferentiated BM-MSCs) or at Day 7 (.98±2.86) (p =
0.9) of differentiation, over control (Figure 17). Instead, CHOP10 continued to be
expressed at basal level at Day 14, (1.24±2.84) (p = 0.9) and Day 21 of differentiation
(1.02±1.04) (p = 0.9) (Figure 17).
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Figure 17: Differential expression of CHOP10 during adipogenic differentiation of BMMSCs in 2D and PuraMatrix based 3D culture. qPCR analysis shows relative change in
CHOP10 expression (relative to undifferentiated hBM-MSCs) at Day 3, Day 7, Day 14,
and Day 21 of differentiation, normalized to GAPDH. n = 3 and error bars = standard error
of the mean. "*" means p< 0.05, "**" means p< 0.01, "***" means p< 0.001, and "****"
means p<0.0001.
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Chapter 6: Translational analysis of master osteogenic and adipogenic
transcription factor during BM-MSCs differentiation in 2D and 3D culture
system.
6.1 Introduction:
RUNX2 and PPARy are considered the master regulator of osteogenesis and
adipogenesis, respectively. Previous studious suggests that, ectopic expression of these
transcription factors is sufficient to induce osteogenic and adipogenic differentiation in
MSCs or any other cell types and their depletion drastically affect skeleton development
and fat metabolism. Since we found dynamic transcript level expression of RUNX2 and
PPARy at different stage of differentiation, we sought to evaluate if their protein level
expression correlate with their transcript level expression.
With equal amount of total protein from all the 2D and 3D protein extracts, we
performed SDS-PAGE and transferred the separated protein to a PVDF membrane for
Western blotting. Following incubation with RUNX2, PPARy, and GAPDH antibodies,
we have found that compared to control (Day 0, undifferentiated) samples, there is slight
increase of RUNX2 protein expression at Day 3 of osteogenic differentiation in 2D culture
system, with marked elevation of RUNX2 protein at Day 7 of osteogenic differentiation
(Figure 18). Such protein level expression of RUNX2 is consistent with its transcript level
change during osteogenesis; although, relative change of protein level between Day 3 and
Day 7 of differentiation is much stronger than its transcript level difference. Surprisingly,
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we did not find any RUNX2 protein in our 3D culture extracts from osteogenic
differentiation, at Day 0, Day 3, and Day 7 despite high level of total protein content found
in the corresponding 3D protein extracts (Figure 18). We speculate that residual RAD16
oligopeptide from the PuraMatrix hydrogel might interfere with RUNX2 antibody binding
to corresponding RUNX2 proteins in the membrane. Such interaction might be highly
selective between RAD16 and RUNX2 antibodies considering PPARy and GAPDH
antibodies did work for our 3D western blot experiments. It would be useful to analyze
RUNX2 protein expression in 3D osteogenic differentiation samples using RUNX2
antibodies from different vendors or host animal.
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Figure 18: Western blot analysis of RUNX2’s protein level expression between 2D and
3D cultured BM-MSCs at Day 0 (control), Day 3 and Day 7 of osteogenic differentiation.
GAPDH is used as loading control.
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In the case of PPARγ, its expression at protein level was markedly increased at Day
3 of adipogenic differentiation of BM-MSCs in 2D culture system; however, we did not
find any noticeable expression at Day 7 of differentiation (Figure 19). Interestingly, in 3D
culture system we found noticeably high expression of PPARy at Day 7 of differentiation
compared to control. However, we did not find any expression of PPARy at Day 3 of
adipogenic differentiation in the 2D culture system (Figure 19). As we expected, GAPDH
was expressed at a similar level throughout the osteogenic and adipogenic differentiation,
in both 2D and 3D culture system (Figures 18,19).
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Figure 19: Western blotting analysis of PPARγ’s protein level expression between 2D and
3D cultured BM-MSCs at Day 0 (control), Day 3 and Day 7 of adipogenic differentiation.
GAPDH is used as loading control.
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Chapter 7: Discussion and Conclusion.

Discussion:
Osteogenesis in MSCs in vitro is initiated by supplementing MSCs growth medium
with osteo-inductive supplements such as Dexamethasone, L-ascorbate and β glycerol-3phosphate (Pittenger, 2008; Castren et al., 2015). Together, these supplements activate a
series of signaling cascades of which BMP and WNT signaling pathway is of significant
importance with regards to instigating osteogenic commitment in MSCs (Figure.3). WntB-catenin pathway not only inhibits pro-adipogenic transcription factor C/EBPα and
PPARγ – the master adipogenic transcription factor, it also activates Runx2 - the master
osteogenic transcription factor - as well as Dlx5 - another key osteogenic transcription
factor (Kang et al., 2007). BMP-Smad signaling on the other hand directly activates Runx2
and promotes osteogenesis whilst restricting myogenic differentiation (Lee et al., 2000).
Activated Runx2 then differentiates MSCs or pre-osteoblast progenitors to pre-osteoblast
and immature osteoblast (Komori, 2010; Fakhry et al., 2013). OSX is upregulated during
MSCs-to-preosteoblast transition and in association with RUNX2, OSX promotes
preosteoblast-to-immature osteoblast transition. Differentiation of immature osteoblast to
mature osteoblast requires activation of factors associated with extracellular matrix protein
production and matrix maturation such as Fra1 and Atf4 hBM-MSCs (Komori, 2006).

64

In osteogenic differentiation experiments in 2D culture system, we found that
compared to undifferentiated hBM-MSCs, expression of RUNX2 increases significantly
about 1.6 fold, 1.9 fold, 2.02 fold, and 3.6 fold at Day 3, Day 7, Day 14, and Day 21 of
osteogenic differentiation, respectively (Figure 12). However, in a previous study with
murine MC3T3-E1 preosteoblast cell line, Xiao et al., (1998) showed that Runx2 increases
about 1.3-fold, 1.5 fold, 2.1 fold, 2.8 fold, and 3.0 fold at Day 0.5, Day 1, Day 2, Day 4,
and Day 6 of osteogenesis, respectively (Xiao et al., 1998). Although RUNX2 expression
pattern (upregulation) during osteogenesis in murine preosteoblast cell line correlates with
that of in hBM-MSCs cells, the relative expression level of RUNX2 at different time points,
however, do vary between these two cell types. One plausible rationale behind such
variation might be the difference in developmental progression between MSCs and preosteoblast cells. Pre-osteoblast cells are already committed to osteogenic differentiation
and expected to express Runx2 already whilst BM-MSCs or MSCs need to commit to
osteogenic lineage in response to osteogenic stimuli and then convert to preosteoblasts.
The developmental timing and epigenetic/transcriptional changes required for such
progression might explain relative difference in RUNX2 transcript level at different time
point during osteogenesis, between different cell types.
In our 3D culture system, RUNX2, however, continued to be expressed at a basal
level until Day 7 of differentiation (Figure 12). Interestingly, at Day 14, RUNX2 expression
significantly increases about 3.4 fold and continues to increase with an 8.9 fold increment
over control at Day 21 of differentiation (Figure 12). Although the upregulated expression
pattern of RUNX2 in 3D culture system is similar to that of 2D culture system, we have
found significant upregulation of RUNX2 at Day 14 and Day 21 of osteogenesis in 3D
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culture system. Marked upregulation of RUNX2 at the late stage of osteogenic
differentiation in 3D culture system suggests improved osteogenesis. Considering the
differentiation process itself is very inefficient - only a portion of the entire stem cell
population terminally differentiates, it is possible that during osteogenic differentiation of
hBM-MSCs in 3D peptide hydrogel system, only a small fraction of encapsulated hBMMSCs enters differentiation at Day 3 or Day 7 while a large number of undifferentiated
hBM-MSCs progress towards osteogenesis at between Day 14 and Day 21.
As anticipated, RUNX2’s protein level expression does correlate with its transcript
level expression in 2D culture system. Our western blotting experiments have found that
compared to control (Day 0), RUNX2 protein level slightly increases at Day 3 of
differentiation whereas a marked elevation of RUNX2 protein was found at Day 7 of
osteogenic differentiation in 2D culture system (Figure 18). Surprisingly, we did not find
any RUNX2 protein in our Day 3, Day 7 samples for osteogenic differentiation in the 3D
cultures system. Considering our Bradford quantification showed high level of total
proteins in Day 3 and Day 7 extracts from 3D culture whereas our gene expression analysis
only showed basal level RUNX2 transcript expression at Day 3 and Day 7 of differentiation
in 3D culture, we propose that basal level RUNX2 mRNA expression, just like
undifferentiated BM-MSCs, might be a possible cause for not detecting RUNX2 proteins
at Day 3 and Day 7 of differentiation.
Osx is another key regulator of osteogenesis, functioning downstream of Runx2
and Osx expression is directly modulated by Runx2 (Nakashima et al., 2002) (Nishio et
al., 2006). Considering Osx expression is contingent upon that of Runx2 (Nakashima et al.,
2002), Osx is expected be expressed at early stage of differentiation. From our 2D gene
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expression experiment, we have found that compared to control (Day 0), OSX expression
significantly upregulates at Day 3, showing 13.3 fold increment over control in 2D culture
the (Figure 13), supporting existing tenet. However, OSX expression is downregulated at
Day 7 about 12-fold, and then continues to express at an equilibrium rate (1.6 fold
increment over control) at Day 14 and Day 21.
Surprisingly, in our 3D culture experiment, OSX expression is actually
downregulated at Day 3 and Day 7 of osteogenesis by about 5 fold and 20 fold respectively.
However, starting Day 7 OSX expression is upregulated 2.8 fold and 5.4 fold at Day 21
over control. Downregulation of OSX at the early stage of differentiation in 3D culture
system compared to 2D culture system might be associated with low level of RUNX2
expression at Day 3 and Day 7 of differentiation in 3D culture system.
Twist is a negative regulator of osteogenesis and previous studies found that Twist
expression is repressed during the early phases of osteogenesis, preferably by Runx2 (Lee
et al., 1999) (Hayashi et al., 2007). In our 2D culture experiments, we have found that
TWIST expression is initially upregulated at Day 3 (about 9 fold over control) of
differentiation and then down regulates about 2 fold at Day 7 over Day 3(7.9 fold over
control) of differentiation. However, TWIST expression is repressed at late stage of
differentiation marked by basal level expression at Day 14 and Day 21. This observation
is consistent with TWIST’s function in inhibiting osteogenesis. In our 3D culture system,
TWIST expression, however, is downregulated about 1.6 and 2.2 fold at Day 3 and Day 7
of differentiation. Surprisingly TWIST expression returns to basal level expression at Day
14 and Day 21 which suggests that TWIST has a novel expression pattern in 3D system.
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Adipogenesis in MSCs or preadipocyte progenitors also proceed as osteogenesis.
MSCs or pre-adipocytes received adipogenic stimuli in form of adipogenic
Dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), indomethacin, and insulin
(Verseijden et al., 2009).
Upon exposure to these differentiation inducers, MSCs or preadipocyte precursors
undergoes series of transcriptional and epigenetic remodeling and commit to adipogenic
lineage by converting into pre-adipocytes. Upregulation of Erg2, and CREB are very
crucial at this stage of lineage commitment (Rosen and MacDougald, 2006; Tang and Lane,
2012). Erg2 and Creb then activates C/EBPβ which is upregulated in preadipocytes,
followed by activation of C/EBPγ expression. During terminal differentiation of
preadipocytes to mature adipocytes, activated C/EBPβ transactivates C/EBPα, which then
activates PPARγ – the master adipogenic regulator (Cristancho and Lazar, 2011). PPARγ
and C/EBPα have an inbuilt auto regulatory feedback system where activated PPARγ
autoactivates itself as well as C/EBPα. C/EBPα-PPARγ autoregulation continues till the
pro-adipocytes differentiate into mature adipocytes. In addition to terminally
differentiating into mature adipocytes, both PPARγ and C/EBPα play key role in
maintaining mature adipocyte identity (Cristancho and Lazar, 2011; Tang and Lane, 2012).
In our adipogenic differentiation experiments with hBM-MSCs, we have found
significant upregulation of PPARy expression at Day 3 of differentiation in both 2D and
3D culture system (9.9 fold and 41-fold respectively) while PPARy expression significantly
downregulated at Day 7 in both systems, with maximum downregulation in 3D culture
system. However, PPARy is again upregulated at Day 14 and Day 21 of differentiation in
both 2D and 3D culture system although such elevation of PPARy expression was more
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prominent in 2D culture system (Figure 15). Elevated expression of PPARy in both 2D and
3D culture suggests increased adipogenesis potential.
In Western blot experiments, we found significantly increased level of PPARy
protein at Day 3 of differentiation but not in Day 7 of differentiation which consistent with
results from adipogenesis in 3T3-L1 preadipocytes where PPARy proteins were more
prominent in Day 3 and 4 but decreased afterwards (Prusty et al., 2002). Surprisingly, in
our 3D culture system we did not find noticeable amount of PPARy protein at Day 3, but
significantly high amount of PPARy in Day 7 (Figure 18). High PPARy expression at later
phase of differentiation in 3D culture system proposes a delay in differentiation process;
while hBM-MSCs commits and starts differentiating in 2D culture system, hBM-MSCs in
3D culture system first adopt themselves to the 3D microenvironment, make changes to
gene expression and metabolic profile prior to committing to differentiation.
Another possible reason for not observing any expression of PPARγ at Day 7 of
differentiation in 2D might be very low level PPARγ which could not be detected by the
imaging system or unstable binding of the secondary anybody and subsequent detachment
during washing steps.
C/EBPα is another key transcription factor regulating adipogenesis, in particular
terminal differentiation of pre-adipocytes to mature adipocytes (Cao et al., 1991; Yeh et
al., 1995; Jiang and Lane, 2000). C/EBPα expression is upregulated at the late state of
adipogenesis, mostly between Day 5-8 in 3T3-L1 preadipocyte cell line (Cao et al., 1991;
Yeh et al., 1995; Jiang and Lane, 2000).
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Surprisingly, in our 2D differentiation experiments with hBM-MSCs, C/EBPα
expression upregulated about 890 fold at Day 3 of differentiation, but markedly
downregulated by 9 fold over control at Day 7 of differentiation (Figure 16). With slight
downregulation over Day 7 at Day 14 of differentiation, C/EBPα expression again
upregulated at Day 21. Except the early phase of differentiation, C/EBPα expression during
the late phase of adipogenic differentiation correlates with that of in preadipocyte cell line.
We speculate that high expression C/EBPα during early phase of differentiation in hBMMSCs may be due to the species-specific difference. Also, high C/EBPα expression in the
early phase of differentiation might jump start PPARγ expression for enhanced
adipogenesis. Interestingly, C/EBPα expression pattern in our 3D culture system does not
correlate with that from 2D culture system. In particular, we have found significant
downregulation at Day 3 of differentiation (6.6 fold over control) while C/EBPα continues
to be expressed at low level or at basal level throughout the entire differentiation process
(Figure 16). Such marked expressional difference of C/EBPα between 2D and 3D culture
system could arise from difference in morphology, differentiation capacity, but most
importantly global chromatin changes. It would be interestingly to explore how C/EBPβ,
an early phase C/EBP transcription factor is expressed during adipogenesis in 3D culture
system using qPCR or RNASeq experiments followed by western blot.
CHOP10 is a major negative regulator of adipogenesis that impedes adipogenic
differentiation by limiting DNA binding ability of C/EBPβ (Batchvarova et al., 1995; Tang
and Lane, 2000). From our 2D gene expression experiments we have found that CHOP10
expression is significantly downregulated at Day 3 of differentiation compared to control
(about 3 fold) and remained suppressed throughout the entire differentiation (Figure 17).
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This observation is consistent with results by Tang et al., 2000 who found that CHOP10
expression sharply plummets within 24h of differentiation of 3T3-L1 preadipocytes. Our
3D experiments, however, showed different expression pattern of CHOP10; slight increase
in CHOP10 expression was found in Day 3 compared to control which downregulated at
Day 7. CHOP10 expression increased at Day 14 but returned to basal level expression at
Day 21 (Figure 17). Difference in CHOP10 expression between 2D and 3D culture hBMMSCs differentiation may be associated with change in cell behavior in 3D
microenvironment as well as active methylation of CHOP10 promoter in 3D culture
system. It would be interesting to analyze CHOP10 promoter’s DNA methylation level
between 2D and 3D culture, using bisulfite sequencing technique.
Another key finding of this study is that besides OSX and C/EBPα, expression of
RUNX2, TWIST1, PPARγ, and CHOP10 is significantly (p < 0.00001) lower in
undifferentiated hBM-MSCS from 3D culture than undifferentiated hBM-MSCS from 2D
culture. In addition to the osteogenic and adipogenic transcription factors, we noticed
significantly low-level expression of GAPDH transcripts (p < 0.00001) in 3D cultured
samples compared to the 2D culture system. One of the probable rationales behind low
GAPDH expression at mRNA and protein level in 3D culture system over 2D culture
system is that hBM-MSCs in 3D PuraMatrix hydrogel might be adapting to stress exerted
by the low pH of the matrix and that might affect hBM-MSC’s glycolytic activity as well
as activating endoplasmic reticulum (ER) stress pathway induced unfolded protein
response (UPR) (Sano and Reed, 2013). Also, being able to reorganize the actin
cytoskeleton and being able to interact with neighboring BM-MSCs in 3D
microenvironment might lead to a new metabolic profile adapted by the 3D cultured BM-
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MSCs which may lead to changes in energy metabolism as well as GAPDH expression. It
would be interesting to analyze expression of key genes associated ER stress pathway or
UPR pathway such ATF4, ATF6, CASR, CHOP, GADD34, IRE1α, JNK, or PERK, in 3D
encapsulated undifferentiated hBM-MSCs and compare them to their 2D counterpart (Sano
and Reed, 2013). Considering, CHOP is one of the key regulators of ER-UPR stress
pathway and play cardinal role in osteogenesis/adipogenesis, we speculate that reduced cell
viability and differential gene expression pattern of GAPDH, RUNX2, TWIST1, PPARγ,
and CHOP10 in 3D cultured BM-MSCs is induced by ER-UPR stress pathway activation
via PERK-ATF4-CHOP signaling, during encapsulation of BM-MSCs (Chan et al., 2017;
Xu et al., 2017).
Considering our gene expression analysis was done by normalizing expression of
each transcription factor to GAPDH expression observed in 2D or 3D culture system and
GAPDH expression is relatively lower in 3D culture system than its 2D counterpart, slight
difference in expression level of these transcription factors in 3D culture system might be
due to the difference in GAPDH expression in 3D. We propose that when analyzing gene
expression in PuraMatrix hydrogel based 3D culture, multiple reference or normalizing
genes should be analyzed and included in the analysis since GAPDH is not stable across
different culture system. In this regard, 18S rRNA and Tata binding protein (TBP) could
be potential candidates.
Accumulating evidence corroborates that 3D culture system greatly differs from
2D culture in terms of dimensionality, structure and function of extracellular matrix inside
the 3D matrix, and topological effect of the 3D matrix on cell’s shape, function and
differentiation (Guilak et al., 2009; Lutolf et al., 2009).
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In particular, one of the key differences between 2D and 3D culture system is the
ability of cells to reorganize themselves and interact with the extracellular matrix more
potently due to the increased surface area and dimensionality of the 3D matrix/scaffold. As
a result, cells encapsulated or maintained in 3D scaffold/matrix are capable of adopting
new morphology/shape. In our study, we have found that BM-MSCs encapsulated in 3D
PuraMatrix hydrogel reorganize into spherical shape in contrast to their native spindle
shape observed in 2D culture. Interestingly, multiple studies corroborate that the shape of
cells plays a substantial role in modulating cells function and differentiation. Using human
capillary endothelial cells, Chen et al., (1997) showed that cell survival and apoptosis is
largely dependent on cell shape; cellular shapes resulting from limited cell spreading,
which is achieved by controlling cell spreading on micropattern surface with different
aspect-ratio, coated with ECM proteins, is typically associated with more apoptosis
whereas cell shapes resulting from unconstrained spreading, mostly due to large surface
area and more opportunity to interact with the ECM, promote cell growth and survival
(Chen et al., 1997). Particularly, in hBM-MSCs, cell shape has been found to be a key
determinant of MSCs differentiation. By controlling hBM-MSCs shape using
micropatterning technique, McBeath et al., (2004) have shown that hMSCs that are unable
to spread and adopts round shape undergoes adipogenesis whereas BM-MSCs that adhere,
and spread on the surface adopts flattened morphology and preferentially differentiates into
osteogenic lineage (McBeath et al., 2004). A similar observation was reported by Kilian et
al., (2010) who showed that limited cell spreading promotes adipogenesis while large
surface area allowing greater cell spreading promotes osteogenesis (Kilian et al., 2010).
Interestingly, McBeath et al., (2004) found that actin-cytoskeleton plays a crucial role in
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determining cell shape and lineage commitment. In fact, chemical disruption of actin
filament organization or inhibition of myosin generated cytoskeletal tension leads to round
cellular shape that promotes adipogenesis and limits osteogenesis and this modulation is
directly controlled by RhoA GTPase and Rho kinase (ROCK) (McBeath et al., 2004). In
our study, we found that encapsulated hBM-MSCs adopt a round morphology in
PuraMatrix based 3D culture. Based on the observations by McBeath et al., (2004) and
(Kilian et al., 2010), round shape is indicative of adipogenic differentiation potential.
Interestingly, in our gene expression study, we found that in the early stage of
differentiation (at Day3), PPARy is significantly increased compared to RUNX2 under
adipogenic and osteogenic differentiation condition which might suggests the role of round
morphology of 3D encapsulated hBM-MSCs in promoting PPARy expression. It would be
interesting to analyze expression of osteogenic and adipogenic transcription factors in 3D
encapsulated BM-MSCs without thee differentiation induction over several weeks to
validate if round morphology of encapsulated BM-MSCs alone can induce adipogenesis or
limit osteogenesis.
Another critical physical property of 3D matrix that directly modulate cells
function, viability, and differentiation is matrix stiffness/elasticity (Yang et al., 2017). In
addition to regulating cell proliferation, migration, and apoptosis, matrix elasticity/stiffness
also regulate stem cell self-renewal and differentiation. For instance, both Engler et al.,
(2006) and Huebsch et al., (2010) proved that MSCs preferentially undergo osteogenesis
when the stiffness of the hydrogel is intermediate to rigid whereas soft matrices favor
neurogenic commitment (Engler et al., 2006; Huebsch et al., 2010).
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Recent studies have shown that matrix stiffness or elasticity generates mechanical stimuli
which are transmitted through integrins and relayed to focal adhesion (FA) kinase (FAK)
to activate RhoA and ROCK mediated actomyosin contraction and actin reorganization
(McBeath et al., 2004; Lv et al., 2015). Particularly in stiffer substrate which promotes
osteogenesis, (Shih et al., 2011), matrix stiffness-induced mechano-transduction increases
ROCK, FAK, and ERK1/2 expression which ultimately lead to increased level of RUNX2
expression and osteogenic fate.
In our 3D experiments, we used 0.125% PuraMatrix hydrogel to encapsulate and
maintain hBM-MSCs for differentiation. Considering stock PuraMatrix is a 1% hydrogel
system, 0.125% represents a much elastic hydrogel. Considering we found significantly
increased level of PPARy expression at early stage of differentiation compared to RUNX2
at the same time point of differentiation, we speculate that 0.125% hydrogel may promote
adipogenic differentiation over osteogenesis. It would be interesting to analyze osteogenic
or adipogenic potential of BM-MSCs maintained in much stiffer hydrogel such as 0.5%,
0.75% or 1% hydrogel.
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Conclusion:
In addition to being an excellent platform/model system to study stem cell biology,
lineage commitment, and epigenetic/transcriptional gene regulations, mesenchymal stem
cells (MSCs) offer unprecedented opportunity in cell-based therapy, tissue engineering,
and regenerative medicine, largely owing to MSC’s multilineage differentiation potential
and immune modulatory property. Many studies are already underway employing MSCs
for bone/cartilage repair or bone tissue engineering (Lin et al., 2018), treating cerebral
ischemic stroke (CIS) (Ward et al., 2018) and sepsis (Zheng et al., 2018), for liver
regeneration (Fiore et al., 2018), to treat primary biliary cholangitis (PBC) (Arsenijevic et
al., 2017) and so on.
Despite such remarkable advances in clinical application of MSCs, little progress
has been made in uncovering many fundamental aspects of MSC biology such as the
transcriptional and epigenetic basis of MSC multipotency and differentiation as well as
how tissue origin affects MSCs differentiation and immune-modulation. In particular,
MSCs have been found to exhibit substantial cell-to-cell variability within same the same
MSC population, between different tissue sources, and between donors (Phinney, 2012;
McLeod and Mauck, 2017). Surprisingly, most studies do not account for this inherent
heterogeneity of MSCs when analyzing MSCs functionality, differentiation, and
immunomodulatory function. Inadequate characterization of multipotent MSCs not only
undermines their application in cell-based therapy and regenerative medicine,
transplantation of transformed MSCs or MSCs with highly heterogenous genetics
background may lead to uncontrolled differentiation, tumor development and cancer
metastasis in vivo (Chang et al., 2015; Li et al., 2018).
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Another major limitation of characterizing different aspects of MSCs biology is the
utilization of many different types of MSCs or progenitor cells by different research
groups. Historically, differentiation of MSCs into mesodermal lineages such as osteogenic
or adipogenic have been studied using murine progenitor cell lines such as MC3T3-E1
preosteoblast cell line or 3T3-L1 pre-adipocyte cell lines (Shao and Lazar, 1997; Xiao et
al., 1998). Considering these osteo/adipo progenitor cells are already in a pre-committed
developmental stage of differentiation, the molecular mechanisms underlying osteogenesis
and adipogenesis from multipotent bona fide MSCs are not truly recapitulated in these cell
lines. In fact, in order to translate MSCs into clinical applications, human MSCs should be
employed when investigating different aspects of MSCs biology. To this end, hMSCs from
hiPSCs or hAD-MSCs (highly convenient to collect) could be a possible source of bona
fide multipotent human MSCs.
In this study, we have analyzed osteogenic and adipogenic differentiation of human
bone marrow derived mesenchymal stem cells (hBM-MSCs) to characterize gene
expression patterns of key osteogenic (RUNX2, OSX, TWIST1) and adipogenic (PPARγ,
C/EBPα, CHOP10) transcription factors in human MSCs system. We have found that these
transcription factors are dynamically expressed over the course of osteogenic or adipogenic
differentiation and their expression pattern in hBM-MSCs differs from that of in preosteoblast or pre-adipocyte cell lines. Moreover, we have characterized PuraMatrix peptide
hydrogel system for 3D culturing of human BM-MSCs and have compared expression
pattern of our defined transcription factors at mRNA and protein level between hBM-MSC
maintained in 2D culture and hBM-MSCs encapsulated in a PuraMatrix based 3D culture
system. In addition to adopting a novel morphology/shape in 3D culture system, hBM-
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MSCs show differential expression of RUNX2, OSX, TWIST1, PPARγ, C/EBPα, and
CHOP10 at stages of osteogenic and adipogenic differentiation. Moreover, we speculate
that hBM-MSCs encapsulated in 3D culture system might adopt a novel metabolic profile
marked by downregulation of GAPDH expression. We propose that compared to
conventional 2D culture, a 3D culture system offers more physiological representation of
human MSCs.
However, there are certain limitations inherent to studying stem cell differentiation
and gene expression analysis in both 2D and 3D culture systems. First of all, induction of
differentiation is a stochastic process; despite receiving same differentiation stimuli, only
certain fraction of a stem cell population or seeded cells in the cell culture plates commit
to differentiation. As a result, there are potential sources of variation between different
stem cell populations (biological groups), which may pass onto the analysis of gene/protein
expression of target genes and quantification of differentiation using different staining
protocols.
In addition, encapsulation of BM-MSCs into PuraMatrix peptide hydrogel, which
is a very delicate process, requires high level of meticulousness. PuraMatrix peptide
hydrogel is acidic (pH of 2-2.5); therefor, direct contact of cells (suspended in sucrose
solution) with the hydrogel results in significant cell death, leading to variable number of
viable-cells/wells when encapsulated and seeded in cell culture plates. To minimize cell
death, the hydrogel and sucrose-cell suspension should be mixed and plated very quickly
followed by immediate gelatination of the gel. Moreover, following encapsulation, the pH
of the hydrogel should be calibrated very quickly, by changing the medium multiple times
within next the hour.
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Also, for analyzing gene expression in 3D culture system, multiple reference genes
should be tested and incorporated in the analysis step. We have found that GAPDH, which
is a popular reference/housekeeping gene used for normalization in gene expression
studies, is differentially expressed in hBM-MSCs when they are maintained in PuraMatrix
peptide hydrogel based 3D culture system.
We hope that future studies will focus on overcoming the limitations mentioned
above and explore other aspects of human MSC biology and PuraMatrix peptide hydrogel
based 3D culture system. In particular, expression of key osteogenic and adipogenic
transcription factors should be compared between human MSCs of different tissue origins
to validate if tissue origin affects expression pattern of these transcription factors at
different stages of differentiation, considering existing report suggests that mouse MSCs
of bone marrow origin have an epigenetic predisposition for osteogenic differentiation
(Meyer et al., 2016). Time course experimental system in this regard would be very
productive in uncovering detailed mechanistic insights into lineage specific gene
expression pattern. With regards to PuraMatrix peptide hydrogel based 3D culture system,
it would of great interest to compare epigenetic profile, metabolic profile, cell surface
markers, and the secretome of MSCs/BM-MSCs maintained in PuraMatrix and other 3D
culture system prior to using encapsulated hMSCs for clinical application. High throughput
techniques such as RNA-Seq or array based qPCR/PCR would be very productive to
perform genome wide analysis study (GWAS) to identify differentially expressed genes in
3D culture hBM-MSCs, followed by their gene ontology analysis.
Further functional characterization of PuraMatrix peptide hydrogel based 3D
culture system is essential prior to their application in tissue engineering and clinical
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studies. In particular, topological features such as matrix elasticity, porosity, degradation,
and mechanical loading should be characterized in PuraMatrix peptide hydrogel since these
topological features strongly influence differentiation of MSCs in other hydrogel or 3D
culture system (Guilak et al., 2009; Lutolf et al., 2009).
Hopefully, future studies will resolve existing limitations and further character
PuraMatrix peptide hydrogel to enable their application in disease/tissue modeling or
complex tissue engineering.
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